Ocular Toxicity Associated with Antibody-Drug Conjugates in Cancer Therapy

A 2026 review by Junxiang Zhou compiling data on ocular toxicity from all currently approved antibody-drug conjugates (ADCs). The document, shared on figshare under a CC-BY-4.0 license, analyzes reported adverse events, their incidence, and potential mitigation strategies. It is a 17.8 KB DOCX file.

Use Cases

• Summarizing reported ocular adverse events and their incidence across approved ADCs based on the review's compilation.
• Analyzing potential mechanisms underlying ADC-associated ocular toxicity as discussed in the document.
• Reviewing strategies for toxicity management, including early detection and monitoring, as highlighted in the text.
• Exploring drug development perspectives for mitigating ocular toxicity through target selection and payload optimization.

Strengths

• Focuses on a specific and under-prioritized adverse event (ocular toxicity) in a prominent therapeutic class.
• Compiles data from both clinical development and postmarketing surveillance for all approved ADCs.
• File is openly shared under a permissive CC-BY-4.0 license.

Limitations

• The dataset is a single 17.8 KB document, indicating a very limited scope and scale.
• Row count and column-level documentation are absent; the content is a narrative review rather than structured data.
• Description metadata is limited; actual data quality requires manual inspection after download.

Provenance

Source

figshare

Collection Method

Compilation and analysis from clinical development and postmarketing data, as described in the review.

Freshness

Last updated 2026-04-27 05:16:34; freshness should be verified.